Learn More
PURPOSE To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of tasidotin (ILX651), a novel dolastatin analogue, when administered as a(More)
Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioguanine at a starting dose of 35 mg/m2/day. There were no responses in these(More)
  • 1